Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of ornithine phenylacetate (OCR-002) for hepatic encephalopathy in patients with cirrhosis

Next Previous
Trial Profile

A phase I trial of ornithine phenylacetate (OCR-002) for hepatic encephalopathy in patients with cirrhosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
  • 20 Oct 2017 Results presented in an Ocera Therapeutics media release.
  • 23 Aug 2017 According to an Ocera Therapeutics media release, data from this trial will be presented at the 68th Annual Meeting of the American Association for the Study of Liver Disease (AASLD).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top